Oral Therapeutics

MIAMI, Fla. — September 17, 2026 MIRA Pharmaceuticals announced that its Phase 2a protocol for Ketamir-2 in chemotherapy-induced peripheral...

BOSTON — September 15, 2026 Syntis Bio, Inc. announced results from the 28-day multiple-ascending-dose (MAD) portion of its Phase...

HONG KONG and STANFORD, Calif., June 12, 2026 Simcere Pharmaceutical Group Limited has entered into a strategic research collaboration...

BASEL, Switzerland, June 12, 2026 Novartis announced new Phase III data at the European Academy of Allergy and Clinical...

BOSTON and SHENZHEN, China, June 10, 2026 XtalPi, a global leader in AI and robotics-driven drug discovery, has announced...